Artificial Lung Market By Artificial Lung Type (Oxygenation-Based Artificial Lungs {ECMO Systems, Implantable Oxygenation Devices}, Bioengineered Lungs {Stem Cell-Based, Tissue-Engineered}, 3D-Printed Lungs {Bioprinted, Custom 3D-Printed Prosthetics}), By Application (COPD, ARDS, Lung Transplantation, Pulmonary Hypertension, COVID-19 & Respiratory Failure, Cystic Fibrosis & Genetic Disorders, Other), By Technology (Mechanical Ventilation, Biological Oxygenation Systems, Hybrid Systems), By End-User (Hospitals & ICUs, Specialty Clinics & Lung Transplant Centers, Research & Academic Institutions), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles, And Market Forecast, 2025 – 2035

Industry Outlook

The Artificial Lung Market accounted for USD 2.47 Billion in 2024 and is expected to reach USD 7.63 Billion by 2035, growing at a CAGR of around 10.8% between 2025 and 2035. The Artificial Lung Market develops products that simulate organic lung processes to deliver breathing assistance for severe lung disease patients.

The industry includes ECMO systems together with bioengineered lung substitutes that serve as critical support tools for two patient groups: lung transplant candidates and those with ARDS or COPD. The market grows due to technological progress, mounting respiratory disease cases, and increasing patient need for substitute organs. Bioartificial lungs together with portable artificial lung devices serve as major industrial drivers due to recent advancements in these technologies.

Report Scope:

Market Dynamics

Rising prevalence of respiratory diseases like COPD, ARDS, and pulmonary hypertension

The Artificial Lungs Market is expanding because of Chronic Obstructive Pulmonary Disease (COPD), acute respiratory distress syndrome (ARDS), and pulmonary hypertension cases are increasing worldwide. The worldwide incidence of COPD maintains its position among major disease contributors because people develop it from smoking combined with air pollution hazards and workplace environmental threats. The severe condition ARDS develops from infections or traumas thus requiring complex advanced respiratory support as a treatment method. The lung condition known as pulmonary hypertension progresses as a chronic disease that maintains high blood pressure levels in the respiratory system and has few available treatment methods.

The rising number of people affected by respiratory conditions has created a substantial demand for new respiratory treatment solutions because of population aging as well as environmental changes and city development. Artificial lung systems incorporate two main products which include ECMO devices and bioengineered lungs to provide essential support when traditional treatments do not reach effectiveness. The lack of donor organs prompts these technologies to assist patients while they wait for transplantation or serve as their permanent breathing support. The growing incidence of these diseases keeps driving the necessity to develop artificial lung systems and promote their use on a broader scale.

Increased Investment in Bioengineered & Stem Cell-Based Lungs

Research and development activities involving bioengineered and stem cell-based lungs stimulate innovative market progress in the artificial lung industry. Stem cell and bioengineered lung development incorporates structures of natural functions through scaffolds alongside biological components to treat lung tissue degeneration. These innovative advancements solve the severe deficit of available donor lungs while creating opportunities for new treatment possibilities to help patients affected by COPD and cystic fibrosis.

These technologies receive substantial funding from governmental bodies together with private organizations and academic research institutions which speeds up innovation. The market experiences increased collaboration and growth possibilities because decellularized lung scaffolds and stem cell therapies improve both the performance and accessibility of artificial lungs.

High costs associated with artificial lung devices and procedures

Artificial lung systems and associated treatments have steep price levels, which create major market hurdles. Regular operation and maintenance of ECMO systems and bioengineered lungs demand special technology, expert medical staff, and specific materials. The expenses from artificial lung procedures increase through extended hospital stays, intensive patient observation, and required follow-up care.

High costs associated with artificial lung therapies create barriers to access treatment, especially among low- and middle-income countries, because patients face difficulties paying for life-saving medical solutions. The elevated cost of artificial lung treatments is an obstacle to enhancing market penetration and increasing adoption because of strategic limitations in technology development.

Innovations in miniaturized and implantable devices present future growth potential

The artificial lung market is undergoing substantial growth because manufacturers continue developing miniature implantable devices. Traditional extracorporeal lung assists systems occupation space and restrict patient movement which has created a market need for small compact products or fully implanted solutions. The combination of biomaterial research and microfluidic technology allows scientists to develop artificial lungs with better natural lung resemblance accompanied by enhanced biocompatibility which reduces the risks of thrombosis. The cutting-edge respiratory devices target sustainable respiratory assistance for end-stage lung disease patients who cannot get lung transplants.

Modern smart sensors combined with artificial intelligence-based monitoring systems optimize oxygen levels while quickly detecting complications for overall performance improvement. Bioartificial lung commercialization is expedited through new partnerships with research institutions and biotech firms. Other continuous R&D and technological innovations continue to see a shift towards more patient-friendly solutions that improve quality of life and reduce dependence on hospitals.

Development of portable and wearable artificial lung devices for enhanced mobility

There is a wide market potential for portable and wearable artificial lung devices, allowing patients to get up and move while also improving their quality of life. Patients must be confined to narrow hospital rooms along with the traditional artificial lung systems like ECMO as these remain bulky and cumbersome. The mobility advantage of portable devices makes it possible for patients to maintain their regular activities and free movement throughout treatment for life-saving respiratory support.

These technological developments give special support to patients who need lung transplants as well as patients with chronic respiratory conditions by giving them more independence and easing their treatment experience. The growing efficiency of portable artificial lung technology together with reduced pricing and increased accessibility will drive product market success and lead to better treatment results.

Industry Experts Opinion

“Data science and AI are embedded across our R&D to enable our scientists to push the boundaries of science to deliver life-changing medicines. Lung cancer is the fourth most common cancer and among the top 5 cancers leading to death in India.”

• Sanjeev Panchal, country president and managing director, AstraZeneca India

Segment Analysis

Based on the Artificial Lung Type, the Artificial Lung Market is classified into Oxygenation-Based Artificial Lungs, Bioengineered Lungs, and 3D-Printed Lungs. Out of all the continuously growing Artificial Lung Market segments, Oxygenation-Based Artificial Lungs dominate the overall Artificial Lung Market because healthcare institutions extensively adopt these devices for vital life preservation. ECMO systems represent one of several devices that medical practitioners use extensively to support patients with severe respiratory failure along with ARDS as well as lung transplant candidates. Membrane oxygenators continue leading the artificial lung market because of rising respiratory disease numbers improved device technologies and their expanded clinical applications across both neonatal and adult critical care. Oxygenation-based artificial lungs currently lead the market because they gained regulatory approvals and clinical applications while being further ahead of bioengineered and 3D-printed lungs that are still experimental.

Based on the Application, the Artificial Lung Market is classified into COPD, ARDS, Lung Transplantation, Pulmonary Hypertension, COVID-19 & Respiratory Failure, Cystic Fibrosis & Genetic Disorders, and Others. Currently, the most dominant elements throughout the Artificial Lung Market are acute respiratory distress syndrome and Respiratory Failure since these conditions create the highest mortality rate among critically ill patients who urgently need advanced respiratory support. ARDS progresses from severe infections and trauma and COVID-19 infections and produces fatal oxygenation failure which requires extracorporeal membrane oxygenation (ECMO) together with artificial lung technologies for support. Market dominance results from the growing prevalence of ARDS as well as enhancements in ECMO technology and the rising use of this technology in intensive care facilities. The artificial lung market demands immediate prolonged respiratory support because of ARDS cases thus establishing the segment as the primary area of focus.

Regional Analysis

Currently, In North America, there is a surge in the Artificial Lung Market because medical technology improves along with increasing respiratory disease rates and an aging demographic. The medical region flourishes with strong infrastructure support along with high acceptance rates for new therapies and substantial financial support for analysis. Current market conditions show that the United States leads this sector because major industry companies work alongside positive regulatory environments and broad awareness about artificial lung systems. Market expansion in Canada occurs because of government-backed programs that enable healthcare funding increases. Market demand for ECMO systems and bioengineered lung technologies continues to grow because of increasing numbers of COPD patients and people affected by ARDS. Research institutes together with biotech companies establish innovation partnerships that drive artificial lung development. Challenges exist from high price levels alongside rigorous regulations for this market sector.

The Asia Pacific Artificial Lung Market has great potential for growth since respiratory disorders are rising while healthcare spending increases and medical technology makes advancements. Asia Pacific markets expanded due to China Japan and India because these nations increased investment in critical health infrastructure together with biotechnology research efforts. The urban hospital market is experiencing a growing need for extracorporeal membrane oxygenation systems because chronic obstructive pulmonary disease (COPD) acute respiratory distress syndrome (ARDS) and lung failure rates keep increasing. The market expansion receives further acceleration from both government initiatives that support healthcare access and new medical device companies that operate in the industry. The global industry partners and local companies work together strategically to improve product accessibility in the market. The widespread adoption of these technologies gets restricted through barriers like elevated prices together with low public understanding and strict regulatory standards in specific sections.

Competitive Landscape

The Artificial Lung Market continues to advance through the efforts of major entities such as ALung Technologies, Breethe, Haemair, Lung Biotechnology PBC, McGowan Institute for Regenerative Medicine, MedArray Inc., Michigan Critical Care Consultants, Miromatrix Medical Inc., Draper, Xenios AG, Medtronic Inc., LivaNova PLC, MAQUET GmbH & Co KG, Terumo Corporation, and C.R. Bard Inc. The industry leaders within these organizations establish the forefront of developing advanced medical solutions for respiratory failure together with its associated medical conditions.

This market demonstrates continuous evolution based on recent advancements in its field. The FDA awarded ALung Technologies its approval for the Hemolung Respiratory Support System in December 2021 because this device removes CO₂ effectively from patients experiencing acute respiratory failure. The approval establishes a favorable moment for delivering advanced respiratory support solutions. Technological developments combined with portable and user-friendly device operation along with market adoption cause this market sector to grow. The market is growing because Asia now has the "Healthy Lung Programme" which raises awareness of needs across the region.

Artificial Lung Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In August 2024, Liquidia Corp.'s inhalation medication Yutrepia for lung conditions received provisional approval from the U.S. Food and Drug Administration (FDA). However, because United Therapeutics' Tyvaso DPI now enjoys regulatory exclusivity, official approval and commercial launch are postponed until May 2025. Liquidia has responded by launching a lawsuit contesting this exclusivity.
• In August 2023, The FDA approved Paragonix Technologies' Baroguard donor lung preservation device. This novel gadget extends the preservation period beyond 24 hours by providing a temperature-pressure-controlled environment to safeguard donor lungs throughout transportation. This development may lessen the demand for private charters by enabling the utilization of commercial flights and larger travel lengths.

Report Coverage:

By Artificial Lung Type

• Oxygenation-Based Artificial Lungs

• Extracorporeal Membrane Oxygenation (ECMO) Systems
• Implantable Oxygenation Devices

• Bioengineered Lungs

• Stem Cell-Based Lungs
• Tissue-Engineered Lungs

• 3D-Printed Lungs

• Bioprinted Lungs
• Custom 3D-Printed Prosthetic Lungs

By Application

• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Lung Transplantation
• Pulmonary Hypertension
• COVID-19 and Respiratory Failure
• Cystic Fibrosis and Other Genetic Lung Disorders
• Other

By Technology

• Mechanical Ventilation
• Biological Oxygenation Systems
• Hybrid Systems

By End-User

• Hospitals & Intensive Care Units (ICUs)
• Specialty Clinics & Lung Transplant Centers

• Research & Academic Institutions

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• ALung Technologies
• Breethe
• Haemair
• Lung Biotechnology PBC
• McGowan Institute for Regenerative Medicine
• MedArray Inc
• Michigan Critical Care Consultants, Inc
• Miromatrix Medical Inc.
• Draper
• Xenios AG
• Medtronic Inc.
• LivaNova PLC
• MAQUET GmbH & Co KG
• Terumo Corporation
• C.R. Bard Inc.

Frequently Asked Questions (FAQs)